SOLUTIONS

It’s prime time to harness the power of RNA & AI
A single platform, diverse applications, unique insights

Overview

LITOSeek™ solutions for precision development of novel therapeutics

Immuno pharmaco-dynamic (ImmunoPD) response markers
Predictive biomarkers of response and resistance
Mechanisms of action and resistance
Discovery of safety biomarkers
Digital cytometry & cellular deconvolution
Companion diagnostic (CDx) for patient selection

Commercialized mRNA biomarker products in routine medical practice

World´s first saas business model for AI-RNA

WHAT ARE WE MISSING?

While cancer therapies have significantly improved patient outcomes,
challenges such as variable patient responses and immune-related side effects persist.

AI is revolutionizing cancer care

Our AI-enabled technology platform is at the forefront of this revolution.

The integration of artificial intelligence (AI) into oncology promises to revolutionize cancer care.

Nature Cancer. 2025;6(7):Review article.

SOLUTIONS

Multi-Omics Prediction of Clinical Response

Novi360 Comprehensive Patient Profiling

Multi-Omic Patient Profiling: RNA Immune Dynamics + DNA Tumor Dynamics + Proteomics + other Omics

RNA LBx captures host systemic immune response & patient heterogeneity ( 180 ̊)

Tumor cfDNA LBx captures tumor evolution & patient heterogeneity ( 180 ̊)

NOVI 360 LBx multiomic platform provides comprehensive assessment of disease progression with predictive capabilities

LBx solution can be efficiently implemented in global clinical trials to detect early response to therapy, and leverage multiomic LBx biomarkers to support clinical development of novel therapies

response prediction : LITOSeek™ multimodal lbx provides early according to recist

Case Study #2

Early patient clinical benefit (CB) prediction

Multiomic integration of LBx RNA immunotranscriptome data and LBxctDNA data for:

1. Precise early prediction of patient Clinical Benefit (high specificity)
2. Accurate prediction of N-CB patients (high sensitivity)

a 10-gene RNA panel reveals functionally relevant novel biomarkers

Case Study #2

clinical benefit prediction with LITOSeek™ multimodal LBX

Case Study #2

SOLUTIONS

ImmunoPharmacoDynamics

LITOSeek™ unveils dynamic systemic immune modulation in CRC

Case Study #1

Early patient clinical benefit (CB) prediction

SOLUTIONS

Early Cancer Detaction

Early Cancer Detection Saves Lives

Colorectal Cancer

Colorectal cancer (CRC) can develop suddenly but progresses very slowly before the first symptoms appear.
The five-year survival rate for early stages of the cancer is over 90%, compared to just 13% for late stages of the cancer when symptoms appear!
Colonoscopy is the recommended standard of care for CRC screening when no symptoms are yet present, however, it is invasive, inconvenient, and expensive resulting in low patient compliance.

Our early cancer detection platform offers:

  • ✓ Non-invasive blood tests that can be offered in routine medical practice
  • ✓ First-in-Class, Best-in-Class performances for detection of Advance Adenoma (AA) precancerous lesions – the earliest development stages of CRC
  • ✓ Robust and reliable process for development and validation of new tests with standardized workflows and analytical pipelines for predictive model selection & decisional algorithm development

Colox™ PBMC Commercialization

world´s first saas business model for AI-RNA

Novi360 Comprehensive Patient Profiling

Multi-Omic Patient Profiling: RNA Immune Dynamics + DNA Tumor Dynamics + Proteomics + other Omics

Colox Commercialization on the Swiss Market

  • ✓ Early identification of patients with CRC and AA
  • ✓ Clinically validated in multi-centric study
  • ✓ Patented in the U.S. & Europe
  • ✓ Commercialized in Switzerland in partnership with Unilabs
  • ✓ Colox PBMC sold in routine medical practice since 2015
  • ✓ Insurance coverage by Helsana in Q4 2019
  • ✓ 2021 Felix Burda Award in Medicine & Science Category

Clinical Validation Of Colox

First-in-Class, Best-in-Class AA Detection

52%
AA Sensitivity

 

80%
CRC Sensitivity

 

90%
Specificity
6’000
Colox tests already
sold in Western Switzerland
400
GP’s have already
prescribed Colox